Noah D. Beerman Joins POXEL as Executive Vice President, Business Development and President, US Operations

Download as PDF

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, announced today that Noah D. Beerman has joined the company as Executive Vice President, Business Development and President, US Operations to spearhead Poxel’s expanding presence into the USA. Mr. Beerman will be based in the Boston area, and is responsible for leading Poxel’s global business development efforts, and for continuing to build the Company’s relationships with the US financial community.

“Over the course of his impressive career, Noah has amassed a wealth of experience in designing innovative partnerships and corporate transactions between a broad range of biotechnology and pharmaceutical companies,” said Thomas Kuhn, CEO of Poxel. “In addition, he has been instrumental in building successful organizations, and we welcome him to our core management team and as strategic leadership for establishing Poxel in the US market.”

“I am particularly excited about the road ahead for Poxel, leveraging all the opportunities inherent in its robust pipeline of treatments for type 2 diabetes, most notably its unique drug candidate, Imeglimin,” Mr. Beerman added. “This is a highly promising area for pharmaceutical development and I look forward to working with such an outstanding, cohesive, and motivated team.”

Mr. Beerman has been an executive in the biopharmaceutical industry for more than 25 years and draws on both research and business development experience from his early career, beginning at Repligen, Sandoz, Curis, and Technology Management & Funding. It was at Indevus Pharmaceuticals from 1997 to 2009, where he was responsible for multiple licensing, co-promotion and M&A agreements, that he established an industry-leading profile in corporate development as Chief Business Officer for the company. From 2009-2011, Mr. Beerman was President, CEO, and Director of RXI Pharmaceuticals (now Galena BioPharma), and until 2013 Executive Vice President and Chief Operating Officer at Coronado Biosciences. Most recently he has served as an executive consultant in the biopharmaceutical industry, and Director on the Board of Trasir Therapeutics. Mr. Beerman holds an MBA from Northeastern University’s High Technology Program and a Bachelors of Science in molecular genetics from the University of Rochester.

About Poxel SA

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

Investor relations / Media - France
NewCap
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr
or
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Anca Alexandru, + 49 89 2424 3494
aalexandru@macbiocom.com

Source: POXEL SA

Released May 19, 2015